Blog

Hycells’s Selected PBMC Reconstruction Data Presentation (Part 2)

Release Date:

2026-06-22 12:11

HuPBMC model Due to its rapid establishment (3–4 weeks) and ease of use, it has been widely employed for in vivo efficacy evaluation in tumor immunotherapy. However, the conventional model suffers from a critical limitation: the randomness and uncertainty inherent in donor selection. The root of the problem lies not in the model itself, but in the “seed” cells—PBMCs—introduced into the system.

 

Donor Selection Practices in Different Tumor Models

Hycells is in NPG mouse model In China, systematic screening and validation of PBMC donors have been conducted for multiple tumor indications. 
 

1. Hep G2 hepatocellular carcinoma CDX Model — Screening successful, model stable 
 

The Hep G2 model likewise validated the reliability of the selected PBMCs—immune reconstitution was successful, tumor infiltration was robust, and the model demonstrated stable performance.

 

PBMC Donor Screening in Hep G2

Liver Cancer CDX Model with NPG Mice

     

 

     Immune Cells Reconstitution in PB

     Immune Cells Infiltration in Tumors


 

2. YCC-2 Gastric Cancer CDX Model—Severe Cachexia, Failed Immune Reconstitution


 

In this donor, the recipient mice developed severe cachexia, and no robust engraftment of human‑derived immune cells was detected in either the peripheral blood or the tumor tissue. This case also demonstrates that PBMC donors who have not undergone rigorous screening not only fail to establish an effective model but may also result in complete experimental failure due to GvHD, cachexia, or other confounding factors.

 

PBMC Donor Screening in YCC-2 Gastric Cancer CDX Model with NPG Mice


 

3. HCC 95 lung cancer CDX model—screening successful; model establishment is ongoing.


                   PBMC Donor Screening in HCC 95 Lung Cancer CDX Model with NPG Mice

 

 

 

                                                                        Immune Cells Reconstitution in PB

Hycells continues to expand the validation of his preferred PBMCs across an increasing number of tumor types…

If you are facing challenges such as the short window period and high data variability in huPBMC models, please feel free to contact the Hycells technical team. Based on your specific tumor model and drug type, we will provide expert guidance on donor‑screening strategies and in vitro pre‑matching services. In addition, Hycells offers a well‑stocked inventory of premium‑quality PBMC batches for modeling; scan the QR code below to request a trial shipment of cryopreserved PBMCs. Once the mouse strain is confirmed, we will reach out to recommend an optimal huPBMC batch for your assay.

 

Previous page

G4S Antibodies Enable a New Breakthrough in CAR‑T Cell Function Research | Professor Huang He’s Team Publishes in Nature Cancer, Unveiling a Novel Mechanism Regulating Ferroptosis (IF: 28.5) Quality First, Innovation Driven

Hycells’s Selected PBMC Reconstruction Data Presentation (Part 1)

Next page

Related News

Hycells HiMag™ Immune Cell Sorting Technology Platform | High Purity, High Viability, Versatile Applications—Redefining the Benchmark for Cell Sorting

With the rapid advancement of cell and gene therapies, the industry is placing increasingly stringent demands on the performance, batch-to-batch consistency, and supply-chain reliability of cell-sorting reagents. At present, the domestic market for sorting magnetic beads remains dominated by imported brands, and their high cost of use and uncertain supply have become significant barriers to both research and industrialization in China.

G4S Antibodies Enable a New Breakthrough in CAR‑T Cell Function Research | Professor Huang He’s Team Publishes in Nature Cancer, Unveiling a Novel Mechanism Regulating Ferroptosis (IF: 28.5) Quality First, Innovation Driven

Recently, Professor Huang He’s team at Zhejiang University published in the top oncology journal “…”. Nature Cancer 》published a research paper titled “Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacy.” This study is the first to reveal that Serum iron overload By elucidating the key mechanisms by which ferroptosis induces functional exhaustion of CAR‑T cells, we have proposed a targeted approach. ACSL4 Alternatively, a novel strategy involves using the ferroptosis inhibitor Fer-1 to enhance CAR-T cell persistence and antitumor efficacy.

Hycells’s Selected PBMC Reconstruction Data Presentation (Part 2)

HuPBMC model Due to its rapid establishment (3–4 weeks) and ease of use, it has been widely employed for in vivo efficacy evaluation in tumor immunotherapy. However, the conventional model suffers from a critical limitation: the randomness and uncertainty inherent in donor selection. The root of the problem lies not in the model itself, but in the “seed” cells—PBMCs—introduced into the system.

Hycells’s Selected PBMC Reconstruction Data Presentation (Part 1)

The humanized PBMC-CDX model is an essential tool for in vivo efficacy evaluation of tumor immunotherapy agents. However, significant inter‑donor variability exists in the engraftment efficiency, T‑cell subset differentiation, and the risk of graft‑versus‑host disease (GVHD) among different PBMC donors, which directly impacts model stability and the experimental window.

A Fresh Start, A New Beginning | Hycells’s Brand Identity Fully Reimagined

Every step forward is aimed at fulfilling our mission even more effectively.

Focused on peptide immunogenicity assessment, precisely empowering tumor neoantigens.

In the field of cancer immunotherapy, tumor neoantigen–specific T-cell responses serve as a key metric for assessing peptide immunogenicity. Leveraging its well-established in vitro assay platform, Hycells Biotechnology offers end-to-end services—ranging from initial screening of peptide immunogenicity and antigen‑specific T-cell expansion to validation of tumor cell‑killing activity—thereby supporting the efficient and reliable discovery and validation of neoantigens.